Sunitinib: From rational design to clinical efficacy

Journal of Clinical Oncology

Volumn 25, Issue 7, 2007, Pages 884-896

  Chow, Laura Q M ^a   Eckhardt, S Gail ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AXITINIB; COLONY STIMULATING FACTOR 1; FLT3 LIGAND; IMATINIB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; SEMAXANIB; SORAFENIB; STEM CELL FACTOR; SUNITINIB; VANDETANIB; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VATALANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; COLON CANCER; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IC 50; KIDNEY CARCINOMA; LEWIS CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; ANIMAL; DRUG DESIGN; KIDNEY TUMOR; NEOPLASM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; DRUG DESIGN; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; KIDNEY NEOPLASMS; LEUKEMIA, MYELOCYTIC, ACUTE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRROLES;

EID: 33947504730     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.3602     Document Type: Review

References (112)

1. Arora A, Scholar EM: Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971-979, 2005
2. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
3. Pawson T: Regulation and targets of receptor tyrosine kinases. Eur J Cancer 38:S3-S10, 2002 (suppl 5)
4. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
5. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003
6. Heinrich MC, Blanke CD, Druker BJ, et al: Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-1703, 2002
7. Schmidt-Arras D, Schwable J, Bohmer FD, et al: Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr Pharm Des 10:1867-1883, 2004
8. Mendel DB, Laird AD, Li G, et al: Development of a preclinical pharmacokinetic/pharmacodynamic relationship for the angiogenesis inhibitor SU11248, a selective inhibitor of VEGF and PDGF receptor tyrosine kinases in clinical development. Proc Am Soc Clin Oncol 20:24a, 2002 (abstr 94)
9. Sun L, Liang C, Shirazian S, et al: Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-aminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46:1116-1119, 2003
10. Parikh AA, Ellis LM: The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin North Am 18:951-971, 2004
11. Osusky KL, Hallahan DE, Fu A, et al: The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7:225-233, 2004
12. Sedlacek HH: Kinase inhibitors in cancer therapy: A look ahead. Drugs 59:435-476, 2000
13. Sundberg C, Ljungstrom M, Lindmark G, et al: Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol 143:1377-1388, 1993
14. Skinner MA, Safford SD, Freemerman AJ: RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Res 23:3601-3606, 2003
15. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145, 2000
16. Podar K, Tonon G, Sattler M, et al: The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A 103:19478-19483, 2006.
17. Wakelee HA, Schiller JH: Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: Novel agents with potential in lung cancer. Clin Lung Cancer 7:S31-S38, 2005 (suppl 1)
18. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189, 2000
19. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655, 2002
20. Rini BI: SU11248 and AG013736: Current data and future trials in renal cell carcinoma. Clin Genitourin Cancer 4:175-180, 2005
21. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004
22. Smolich BD, Yuen HA, West KA, et al: The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 97:1413-1421, 2001
23. Giles FJ, Stopeck AT, Silverman LR, et al: SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102:795-801, 2003
24. Laird AD, Vajkoczy P, Shawver LK, et al: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160, 2000
25. Mendel DB, Laird AD, Xin X, et al: In vivo anti-tumor and mechanism of action of SU011248, a potent and selective inhibitor of the VEGF and PDGF receptors. Presented at Am Assoc Cancer Res Meeting, San Francisco, CA, April 6-10, 2002 (poster 5349)
26. O'Farrell AM, Abrams TJ, Yuen HA, et al: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605, 2003
27. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
28. Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766, 2003
29. Pfizer Inc: Investigator's Brochure SU011248 (Pfizer Inc) July 2004. Pfizer Global Research and Development, New York, NY 2004 (unpublished).
30. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006
31. Motzer RJ, Rini BI, Michaelson MD, et al: Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol 23:380s, 2005 (suppl; abstr 4508)
32. Krystal GW, Honsawek S, Kiewlich D, et al: Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res 61:3660-3668, 2001
33. Carter TA, Wodicka LM, Shah NP, et al: Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 102:11011-11016, 2005
34. Moss KG, Toner GC, Cherrington JM, et al: Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 307:476-480, 2003
35. Kacinski BM: CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 27:79-85, 1995
36. Toy EP, Chambers JT, Kacinski BM, et al: The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol Oncol 80:194-200, 2001
37. Abrams TJ, Murray LJ, Pesenti E, et al: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011-1021, 2003
38. Yee KW, Schittenhelm M, O'Farrell AM, et al: Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 104:4202-4209, 2004
39. Pietras K, Hanahan D: A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23:939-952, 2005
40. Marzola P, Degrassi A, Calderan L, et al: Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 11:5827-5832, 2005
41. Morimoto AM, Tan N, West K, et al: Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene 23:1618-1626, 2004
42. Shimono R, Matsubara S, Takamatsu H, et al: The expression of cadherins in human neuroblastoma cell lines and clinical tumors. Anticancer Res 20:917-923, 2000
43. Manning WC, Bello CL, Deprimo SE, et al: Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients (pts) with imatinib-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 22:192, 2003 (abstr 768)
44. Miller KD, Burstein H J, Elias A D, et al: Phase II study of SU11248, a multi-targeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol 23:19s, 2005 (suppl; abstr 563)
45. Demetri GD, Desai J, Fletcher JA, et al: SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol 22:195s, 2004 (suppl; abstr 3001)
46. Chen H, Isozaki K, Kinoshita K, et al: Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int J Cancer 105:130-135, 2003
47. van Spronsen DJ, Mulders PF, De Mulder PH: Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hematol 55:177-191, 2005
48. Bello CL, Sherman L, Zhou J, et al: Food does not affect the pharmacokinetics of SU011248, a multi-targeted receptor tyrosine kinase inhibitor in healthy subjects. Presented at EORTC/AACR/NCI Molecular Targets Meeting, Philadelphia, PA, November 14-18, 2005
49. Houk B, Garrett M, Bello C, et al: Population pharmacokinetics of SU011248 and its primary metabolite SU12662 in oncology patients and healthy volunteers. Presented at EORTC/AACR/NCI Molecular Targets Meeting, Philadelphia, PA, November 14-18, 2005
50. Bello CL, Sherman L, Zhou J, et al: Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: Results from a phase I study in healthy subjects. Anticancer Drugs 17:353-358, 2006
51. Washington C, Eli M, Bello C, et al: The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics (PK) in Caucasian and Asian healthy subjects. Proc Am Soc Clin Oncol 22:138, 2003 (abstr 553)
52. Bello C, Houk B, Sherman S, et al: Effect of rifampin on the pharmacokinetics of SU011248 in healthy volunteers. J Clin Oncol 23:211s, 2005 (suppl; abstr 3078)
53. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
54. Rosen L, Mulay M, Long J, et al: Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 22:191, 2003 (abstr 765)
55. Raymond E, Faivre S, Vera K, et al: Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 22:192, 2003 (abstr 769)
56. Houk B, Bello C, Garrett M, et al: Population pharmacokinetic (PK)- pharmacodynamic (PD) meta-analysis of SU011248 efficacy and tolerability end-points in gastrointestinal stromal tumors (GIST), metastatic renal cell carcinoma (MRCC) and solid tumor patients. Presented at EORTC/AACR/NCI Molecular Targets Meeting, Philadelphia, PA, November 14-18, 2005
57. Desai J, Dileo P, Morgan JA, et al: Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy. J Clin Oncol 23:201s, 2005 (suppl; abstr 3040)
58. Shaheen PE, Tamaskar IR, Salas RN, et al: Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J Clin Oncol 24:242s, 2006 (suppl; abstr 4605)
59. Pande AU, Lombardo JC, Fakih M, et al: Bevacizumab (BV) induced hypertension (HT): A manageable toxicity. J Clin Oncol 24:619s, 2006 (suppl; abstr 13539)
60. Belgore FM, Lip GY, Barford D. Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in haematological cancers: a comparison with breast cancer. Am J Hematol 66:59-61, 2001
61. Eskens FA: Angiogenesis inhibitors in clinical development: Where are we now and where are we going? Br J Cancer 90:1-7, 2004
62. Robert C, Faivre S, Raymond E, et al: Subungual splinter hemorrhages: A clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 143:313-314, 2005
63. O'Farrell AM, Deprimo SE, Manning WC, et al: Analysis of biomarkers of SU11248 action in an exploratory study in patients with advanced malignancies. Proc Am Soc Clin Oncol 21:234, 2003 (abstr 939)
64. Toner GC, Mitchell PL, De Boer R, et al: PET imaging study of SU11248 in patients with advanced malignancies. Proc Am Soc Clin Oncol 22:191, 2003 (abstr 767)
65. Scott A, Mitchell P, O'Keefe G, et al: Tumor perfusion as assessed by oxygen-15-water PET imaging during treatment with SU011248 in patients with advanced malignancies. Presented at EORTC/AACR/NCI Molecular Targets Meeting, Philadelphia, PA, November 14-18, 2005
66. Wang JQ, Miller KD, Sledge GW, et al: Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorg Med Chem Lett 15:4380-4384, 2005
67. O'Farrell AM, Foran JM, Fiedler W, et al: An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9:5465-5476, 2003
68. Fiedler W, Serve H, Dohner H, et al: A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105:986-993, 2005
69. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999
70. Motzer RJ, Mazumdar M, Bacik J, et al: Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18:1928-1935, 2000
71. Rini BI, Sosman JA, Motzer RJ: Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Biology, clinical results and future development. BJU Int 96:286-290, 2005
72. Turner KJ, Moore JW, Jones A, et al: Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62:2957-2961, 2002
73. Sulzbacher I, Birner P, Traxler M, et al: Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 120:107-112, 2003
74. Xu L, Tong R, Cochran DM, et al: Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 65:5711-5719, 2005
75. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
76. Motzer RJ, Rini BI, Michaelson MD, et al: Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol 23:380s, 2005 (suppl; abstr 4508)
77. Rini B, Rixe O, Bukowski R, et al: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol 23:380s, 2005 (suppl; abstr 4509)
78. Escudier B, Szczylik C, Eisen T, et al: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 23:380s, 2005 (suppl; abstr LBA4510)
79. Tamaskar I, Shaheen P, Wood L, et al: Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. J Clin Oncol 24:240s, 2006 (suppl; abstr 4597)
80. Rini BI, George DJ, MD M, et al: Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 24:222s, 2006 (suppl; abstr 4522)
81. Ronnen EA, Kondagunta GV, Lau C, et al: A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24:225s, 2006 (suppl; abstr 4537)
82. Argos Therapeutics Inc: A Translational research study testing the biology of monocyte-derived dendritic cells and immune effector cells from subjects with advanced renal cell cancer currently treated with sunitinib or sorafenib: March 10, 2006 Investigators Protocol. (unpublished) Argos Therapeutics Inc, Durham, NC, 2006
83. NIH: Information on Clinical Trials and Human Research. US National Institutes of Health. http://www.clinicaltrials.gov (http://www.clinicaltrials. gov/ct/search?term=sunitinib&submit=search)
84. NCI/CTEP: US National Institutes of Health. NCI Clinical Trials Information Site. http://www.cancer.gov (http://www.cancer.gov/search/ resultsclinicaltrialsadvanced.aspx?protocolsearchid=2949155)
85. Motzer RJ, Hutson TE, Tomczak P, et al: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24:2s, 2006 (suppl; abstr LBA3)
86. Joensuu H, Fletcher C, Dimitrijevic S, et al: Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3:655-664, 2002
87. Van Glabbeke M, Verweij J, Casali PG, et al: Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23:5795-5804, 2005
88. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004
89. Rankin C, Mehren MV, Blanke C: Dose effect of imatinib in patients with metastatic GIST: Phase III sarcoma group study S0033. J Clin Oncol 22:819s, 2004 (suppl; abstr 9005)
90. Lasota J, Wozniak A, Sarlomo-Rikala M, et al: Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: A study of 200 cases. Am J Pathol 157:1091-1095, 2000
91. Sakurai S, Oguni S, Hironaka M, et al: Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. Jpn J Cancer Res 92:494-498, 2001
92. Burger H, den Bakker MA, Kros JM, et al: Activating mutations in c-KIT and PDGFRa are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 4:1270-1274, 2005
93. de Jong FA, Verweij J: Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors. Expert Rev Anticancer Ther 3:757-766, 2003
94. Weisberg E, Griffin JD: Resistance to imatinib (Glivec): Update on clinical mechanisms. Drug Resist Updat 6:231-238, 2003
95. Demetri GD, George S, Heinrich MC, et al: Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal. Proc Am Soc Clin Oncol 21:814, 2003 (abstr 3273)
96. Davis DW, McConkey D J, Heymach JV, et al: Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248. J Clin Oncol 23:193s, 2005 (suppl; abstr 3006)
97. Demetri G, van Oosterom AT, Garrett C, et al: Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate (IM) therapy in a phase III trial. Presented at Am Soc Clin Oncol Gastrointestinal Cancers Symposium, San Francisco, CA, January 26-28, 2006 (abstr 8)
98. Casali PG, Garrett R, Blackstein ME, et al: Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol 24:523s, 2006 (suppl; abstr 9513)
99. Maki RG, Fletcher JA, Heinrich MC, et al: Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 23:818s, 2005 (suppl; abstr 9011)
100. Antoch G, Kanja J, Bauer S, et al: Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45:357-365, 2004
101. Dileo P, Van Den Abbeele AD, Manola J, et al: Qualitative assessment of 18FDG-PET correlates with clinical benefit in patients (pts) with imatinib mesylate (IM)-resistant GIST treated with the multitargeted tyrosine kinase inhibitor SU11248. Presented at Am Soc Clin Oncol Gastrointestinal Cancers Symposium, 2005 (abstr 8)
102. Norden-Zfoni A, Manola J, Desai J, et al: Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST. J Clin Oncol 23:825s, 2005 (suppl; abstr 9036)
103. Heinrich MC, Maki RG, Corless CL, et al: Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol 24:520s, 2006 (suppl; abstr 9502)
104. De Mulder PH, Roigas J, Gillessen S, et al: A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 24:223s, 2006 (suppl; abstr 4529)
105. George S, Casali PG, Blay J, et al: Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST. J Clin Oncol 24:527s, 2006 (suppl; abstr 9532)
106. Miller KD, Burstein HJ, Elias AD, et al: Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol 23:19s, 2005 (suppl; abstr 563)
107. Deprimo SE, Friece C, Huang X, et al: Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. J Clin Oncol 24:22s, 2006 (suppl; abstr 578)
108. Pfizer Oncology. Clinical trials: Sunitinib. http://www.pfizeroncology. com/ClinicalTrialPO.aspx
109. Kulke M, Lenz H, Meropol NJ, et al: A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). J Clin Oncol 23:310s, 2005 (suppl; abstr 4008)
110. Bello CL, DePrimo SE, Friece J, et al: Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. J Clin Oncol 24:189s, 2006 (suppl; abstr 4045)
111. Socinski MA, Novello S, Sanchez JM, et al: Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. J Clin Oncol 24:364s, 2006 (suppl; abstr 7001)
112. Lenz H, Marshall J, Rosen L, et al: Phase II trial of SU11248 in patients with metastatic colorectal cancer (MCRC) after failure of standard chemotherapy. Presented at Am Soc Clin Oncol Gastrointestinal Cancers Symposium, San Francisco, CA, January 26-28, 2006 (abstr 241)